Entod Pharmaceuticals set to launch Molentod for treating COVID-19

Entod Pharmaceuticals today said that it is launching a generic version of Molnupiravir under the brand Molentod in India.

A statement from the company said that Entod Pharmaceuticals aims to make the product available as early as possible and that its first batch is already under production. Molentod will be available at retail chemists, pharmacy chains, hospitals and online stores across India at an affordable price to patients with an MRP of Rs 649 per strip of 10 capsules.

The statement quoted Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, as saying that the emergency approval of Molnupiravir by DCGI is an important decision taken by the Indian government and it will help in protecting India from the Omicron wave.

The recommended dose of the drug is four capsules (800 mg) twice a day for five days. The duration of treatment of Molnupiravir is much shorter compared to other therapies, which is a significant advantage as it reduces the pill burden and enhances compliance. Molnupiravir improves patient compliance for non-hospitalised patients and reduces the chance of hospitalisation or death for high-risk populations, said the statement.

Anjula Masurkar, Clinical Director, Entod Pharmaceuticals, said, “……..The short-duration nature of this treatment would ensure enhanced compliance helping the country avoid unnecessary hospitalisations or even deaths in the coming months.”